Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;8(2):131-137.
doi: 10.21106/ijma.321. Epub 2019 Nov 27.

Impact of Highly Active Antiretroviral Therapy on Chronic Hepatitis B Serological Markers among Senegalese HIV Co-infected Children

Abou Ba  1 , Fatou K Ndiaye  1 , Yaay J Djeng  1 , Cecile Cames  2 , Aminata Diack  1 , Ousmane N'diaye  1
Affiliations

Impact of Highly Active Antiretroviral Therapy on Chronic Hepatitis B Serological Markers among Senegalese HIV Co-infected Children

Abou Ba et al. Int J MCH AIDS. 2019.

Abstract

Background: Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) causes complex interactions. The aim of this study was to evaluate the seroprevalence and HBV evolution among HIV coinfected children receiving highly active antiretroviral therapy (HAART).

Methods: A descriptive cross-sectional study was carried out among 252 HIV infected children enrolled in the Hôpital d'enfants Albert Royer, Dakar, Senegal, from April 2013 to March 2015. Clinical characteristics, immuno-virological status, alanine aminotransferase (ALT) levels, and HBV serological marker were taken from the patients' medical records.

Results: Overall, 7 children were HBsAg positive with a determinate prevalence rate of 2.8%. Median age at HIV diagnosis was 3.5 years (1.3-14.4 years). According to World Health Organization (WHO) staging, 40.1% of children were stage 4 and 25.8% were stage 3. Of the 7 HIV/HBV-co-infected children, 6 (86%) received lamivudine alone at initiation of treatment, and only one child received tenofovir associated with emtricitabine. Overall median HAART duration treatment including lamivudine alone or tenofovir+lamivudine (or emtricitabine) was 7.7 years (3.3-11.3). Only the two children (29%) receiving lamivudine during follow-up had high HBV DNA load despite having good immuno-virological status. Suppression of HBV DNA replication was achieved in 5 (71.4%) of 7 children.

Conclusion and global health implication: HIV/HBV coinfection prevalence was low in our study. HBsAg and HBeAg loss were low while suppression of HBV DNA replication was still higher on tenofovir. Screening and monitoring HBV infection among all HIV infected children are required to direct treatment in order to improve children HBV/HIV coinfected outcome.

Keywords: Children; HBV infection; HIV infection; Immunology; Senegal; Serological markers; Serprvalence; Virology; antiretroviral therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors declare that they have no conflicts of interest.

References

    1. Organisation mondiale de la santé(OMS) Hépatite B. [Accessed May 10 2019]. https://www.who.int/fr/news-room/fact-sheets/detail/hepatitis-b .
    1. Matthews PC, Geretti AM, Goulder PJR, Klenerman P. Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa. Journal of Clinical Virology. 2014;61(1):20–33. doi:10.1016/j.jcv.2014.05.018. - PubMed
    1. Soriano V, Poveda E, Vispo E, Barreiro P. Hepatitis B in HIV-infected patients. Clinical Liver Disease. 2013;17(3):489–501. doi:10.1016/j.cld.2013.05.008. - PubMed
    1. Spearman CW, Afihene M, Ally R. Hepatitis B in sub-Saharan Africa:strategies to achieve the 2030 elimination targets. Lancet Gastroenterology & Hepatology. 2017;2(12):900–909. doi :10.1016/S2468-1253(17)30295-9. - PubMed
    1. Wandeler G, Gsponer T, Bihl F, et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. Journal of Infectious Disease. 2013;208(9):1454–1458. doi:10.1093/infdis/jit351. - PubMed

LinkOut - more resources